Find your PDFs fast.
Welcome to the Pubget Medical Subject Headings (MESH) browser. Click on a topic or subtopic below to explore related papers. In the gold box is the most recent paper about the current MESH term, and below are 20 related papers.
Oncolytic Viruses (0):
Recent article
Oncolytic Viruses
Molecular Therapy (19)4 2011
Abstract
We show that apart from its primary direct cancer-killing activity, reovirus oncotherapy overrides tumor-associated immune evasion strategies and confers protective antiprostate cancer immunity. Prostate cancer represents an ideal target for immunotherapies. However, currently available immune inter...
|
PMID: 21245852
PDF is available here.
PDF is available here.
| < More recent | Older article > |
Abstract
We analyzed for the first time the therapeutic efficacy of the oncolytic vaccinia virus GLV-1h68 in two human hepatocellular carcinoma cell lines HuH7 and PLC/PRF/5 (PLC) in cell culture and in tumor xenograft models. By viral proliferation assays and cell survival tests, we demonstrated that GLV-1h...
|
PMID: 21779374
PDF is available here.
PDF is available here.
Clinical Cancer Research (17)6 2011
Abstract
We examined the effect of Chase-ABC on OV spread and efficacy....
|
PMID: 21177410
PDF is available here.
PDF is available here.
Molecular Therapy (18)11 2010
Abstract
We inserted palindromic E2F-binding sites into the endogenous E1A promoter. The insertion of these sites controlling E1A-Δ24 results in a low systemic toxicity profile in mice. Importantly, the E2F-binding sites also increased the cytotoxicity and the systemic antitumor activity relative to wild-ty...
|
PMID: 20808288
PDF is available here.
PDF is available here.
Journal of Virology (84)16 2010
Abstract
We have constructed a novel oncolytic HSV-1 recombinant, KTR27, whose replication can be tightly controlled and regulated by tetracycline in a dose-dependent manner. Infection of normal replicating cells as well as multiple human cancer cell types with KTR27 in the presence of tetracycline led to 1,...
|
PMID: 20519407
PDF is available here.
PDF is available here.
Abstract
Oncolytic virus therapy (OVT) is a promising treatment modality for cancer that uses tumor-specific defects to target cancer cells selectively. An increasing number of replicating viruses has been demonstrated to cure cancer in a diverse set of animal models. Accordingly, many such viruses have ente...
|
PMID: 20677090
PDF is available here.
PDF is available here.
Abstract
A significant limitation to the use of viruses as systemic vectors is the susceptibility of the vector to inactivation and clearance by various blood components. Despite much focus on antibodies as the primary neutralizing molecules in blood, other mechanisms inactivate and clear virus particles fro...
|
PMID: 20677092
PDF is available here.
PDF is available here.
Abstract
The use of viruses as therapeutic agents against cancer is an old concept that has had a significant revival in the past two decades, in parallel with advances in methods to modify viral genomes genetically. From the initial stage of proof of concept, the field of virotherapy quickly progressed to t...
|
PMID: 20677091
PDF is available here.
PDF is available here.
Gene Therapy (17)7 2010
Abstract
We sought to determine whether antiangiogenic pretreatment increases the antitumor efficacy of systemic virotherapy by increasing virus uptake into tumor. Virus biodistribution and antitumor effects were monitored in tumor-bearing mice given antihuman vascular endothelial growth factor (VEGF) or ant...
|
PMID: 20508601
PDF is available here.
PDF is available here.
Abstract
We assessed whether the presence of NIS in the viral genome affects the therapeutic efficacy of the oncolytic adenovirus dl922-947 following intraperitoneal administration, in a mouse model of peritoneal ovarian carcinoma.
We generated AdAM7, a dl922-947 oncolytic adenovirus encoding...
|
PMID: 20140612
PDF is available here.
PDF is available here.
Annals of Surgery (251)6 2010
Abstract
Our results indicate that intratumoral injection of OBP-301 mediates effective in vivo purging of metastatic tumor cells from regional lymph nodes, which may help optimize treatment of human cancer, especially gastrointestinal malignancies....
|
PMID: 20485131
PDF is available here.
PDF is available here.
Abstract
The radiochemical purity of I/I-KH901 was over 95%. I-KH901 stimulated massive expression of granulocyte-macrophage colony-stimulating factor in tumor cells. Twenty-four hours after the addition of I-KH901, the concentrations of granulocyte-macrophage colony-stimulating factor were 183.27+/-6.90 and...
|
PMID: 20147862
PDF is available here.
PDF is available here.
Cancer Gene Therapy (17)5 2010
Abstract
We found that reovirus infection suppresses hypoxia inducible factor (HIF)-1alpha protein levels (but not transcript abundance) in colon cancer HCT116 cells under CoCl(2) or hypoxia. Reovirus infection was able to reduce HIF-1alpha levels in both von Hippel Lindau (VHL)-/- renal carcinoma A498 and p...
|
PMID: 20075985
PDF is available here.
PDF is available here.
Abstract
To investigate the inhibitive effects of chimeric oncolytic adenovirus SG235 on leukemia cells in vitro.
The ability of SG235 to infect leukemia cells and the expression of CD46 on blasts from the patient with leukemia were detected by flow cytometry (FACS). The cytotoxicity of the virus was evaluat...
|
PMID: 20544981
PDF is available here.
PDF is available here.
Molecular Therapy (18)5 2010
Abstract
A number of oncolytic virus (OV) candidates currently in clinical trials are human viruses that have been engineered to be safer for patient administration by limiting normal cell targeting and replication. The newest OVs include viruses that cause no disease in humans, yet still hav...
|
PMID: 20160706
PDF is available here.
PDF is available here.
Human Gene Therapy (21)4 2010
Abstract
We hypothesized that engineering VSV to express the potent T cell costimulatory molecule CD40 ligand (VSV-CD40L) would enhance virotherapy with concomitant priming of melanoma-specific T cells. However, we observed no difference in antitumor efficacy between the parental VSV-GFP and VSV-CD40L. In co...
|
PMID: 19922169
PDF is available here.
PDF is available here.
Gene Therapy (17)3 2010
Abstract
We report that the growth compromised herpes simplex virus type 2 (HSV-2) mutant, DeltaPK, has strong oncolytic activity for melanoma largely caused by a mechanism other than replication-induced cell lysis. The ratio of dead cells (determined by trypan blue or ethidium homodimer staining) to cells t...
|
PMID: 19798049
PDF is available here.
PDF is available here.
Abstract
Melanoma patients present with elevated levels of Tregs, Ts, and MDSC within established tumors. Direct injection of Oncovex(GM-CSF) induces local and systemic antigen-specific T cell responses and decreases Treg, Ts, and MDSC in patients exhibiting therapeutic responses....
|
PMID: 19915919
PDF is available here.
PDF is available here.
Abstract
A high throughput quantitation protocol is desired to determine the replication of various recombinant oncolytic viruses in vitro. Plaque assay is the classic method for viral infectivity quantitation but is laborious and time consuming; moreover it does not report the oncolytic efficacy of a virus....
|
PMID: 19914292
PDF is available here.
PDF is available here.
Cancer Research (70)3 2010
Abstract
We engineered MV to express the marker peptide carcinoembryonic antigen (MV-CEA virus) to also permit real-time monitoring of viral gene expression in tumors in the clinical setting. Patients with Taxol and platinum-refractory recurrent ovarian cancer and normal CEA levels were eligible for this pha...
|
PMID: 20103634
PDF is available here.
PDF is available here.
Journal of Virology (84)4 2010
Abstract
We found that trimers of the major structural protein (VP) of the parvovirus minute virus of mice (MVM), which have to be imported into the nucleus for capsid assembly, undergo phosphorylation by the Raf-1 kinase. Purified Raf-1 phosphorylated the capsid subunits in vitro to the two-dimensional patt...
|
PMID: 19939915
PDF is available here.
PDF is available here.
Gene Therapy (17)2 2010
Abstract
We hypothesized that unique aspects of the poxvirus life cycle would protect it from attenuation in hypoxic conditions. We characterized and compared the viral protein production, viral replication, cytotoxicity and transgene expression of Lister strain vaccinia virus in a panel of pancreatic cancer...
|
PMID: 19890355
PDF is available here.
PDF is available here.
Oncology Reports (23)2 2010
Abstract
We also determined the optimal order for combining telomelysin treatment and chemotherapy as concurrent treatment, telomelysin treatment first and chemotherapy later, chemotherapy first and telomelysin treatment later for achieving the best anticancer effect. The mRNA expression of hTERT and CAR gen...
|
PMID: 20043095
PDF is available here.
PDF is available here.
Clinical Cancer Research (16)2 2010
Abstract
These data suggest that the novel oncolytic mutant AdDeltaDelta is a promising candidate for targeting of solid tumors specifically in combination with chemotherapeutics....
|
PMID: 20068104
PDF is available here.
PDF is available here.
Acta Oncologica (49)1 2010
Abstract
ADM and DDP enhanced cell killing/inhibiting effects of ZD55-IL-24 in all the tumor cell lines, while no overlapping toxicity was observed in the normal liver cell line L-02. These chemo-agents inhibited the propagation of ZD55-IL-24 in NCI-H460 cells, but did not influence the expression of IL-24....
|
PMID: 19734998
PDF is available here.
PDF is available here.
Journal of Virology (84)2 2010
Abstract
We report the generation of vvdd-VEGFR-1-Ig, a targeted and armed oncolytic vaccinia virus. Tumor targeting was achieved by deletion of genes for thymidine kinase and vaccinia virus growth factor, which are necessary for replication in normal but not in cancer cells. Given the high vascularization t...
|
PMID: 19906926
PDF is available here.
PDF is available here.
Journal of Virology (84)1 2010
Abstract
We applied a novel approach for the treatment of melanoma, using a unique strain of the oncolytic Newcastle disease virus (NDV-HUJ). We found that, unlike chemotherapeutic drugs, NDV-HUJ, a one-cycle replicating virus, overcomes the resistance to apoptosis of melanoma primary cultures that over expr...
|
PMID: 19864394
PDF is available here.
PDF is available here.
Abstract
It is well documented that immunotherapy has a great potential for cancer treatment. The ideal cancer immunotherapeutic strategies should be relatively simple, but able to trick the host's immune system to elicit a robust immune response to the tumor target. Herpes Simplex Virus (HSV) has been engin...
|
PMID: 20686972
PDF is available here.
PDF is available here.
Abstract
Previous irradiation rendered glioma cells fully permissive to H-1PV infection. Irradiation 24 hours prior to H-1PV infection led to increased cell killing most notably in radioresistant glioma cells. Intracellular levels of NS-1, the main effector of H-1PV induced cytotoxicity, were elevated after...
|
PMID: 20224643
PDF is available here.
PDF is available here.
Abstract
cHSF1 enhances the Adel55 cell-killing potential through increasing the viral replication and is a potential therapeutic implication to augment the potential of E1B55kD deleted oncolytic adenovirus by increasing its burst....
|
PMID: 20459615
PDF is available here.
PDF is available here.
Cytokine & Growth Factor Reviews (21)2-3 2010
Abstract
Abstract
We analyzed the therapeutic efficacy of the oncolytic vaccinia virus GLV-1h68 against two human prostate cancer cell lines DU-145 and PC-3 in cell culture and in tumor xenograft models. By viral proliferation assays and cell survival tests, we demonstrated that GLV-1h68 was able to infect, replicate...
|
PMID: 20379368
PDF is available here.
PDF is available here.
Virus/Uirusu (59)2 2009
Abstract
Further attenuated live measles vaccine strains were developed through passages in chick embryo cells or other non-permissive cells from the Edmonston strain. The number of measles patients has reduced through worldwide acceptance of measles vaccine. Measles elimination was achieved in American cont...
|
PMID: 20218334
PDF is available here.
PDF is available here.
Abstract
We review the methods for reovirus modification and their use for generating new reovirus-derived oncolytic agents....
|
PMID: 19916732
PDF is available here.
PDF is available here.
Abstract
Angiogenesis is essential for development and tissue repair, and is controlled by a balance of inhibitors and promoters. Overactive angiogenesis promotes tumor progression and other chronic disorders, including diabetic retinopathy and rheumatoid arthritis. The discovery of angiogenesis inhibitors h...
|
PMID: 20072943
PDF is available here.
PDF is available here.
Abstract
Cancer is a major cause of deaths in humans. Though there has been significant progress in cancer therapy, the limited efficacy and toxicities of current chemo- and radiotherapies have provided an impetus for the search of new therapeutics. A therapeutic approach, which uses viruses for the treatmen...
|
PMID: 20090097
PDF is available here.
PDF is available here.
Molecular Therapy (17)12 2009
Abstract
We expanded the therapeutic window of oncolytic serotype 5 Ad (Ad5) by a genetic modification of hypervariable loop 5 (HVR5) in the capsid protein hexon that prevented infection of hepatocytes due to ablation of binding to blood factors. This oncolytic virus, Ad-GL-HB, had significantly reduced leve...
|
PMID: 19755961
PDF is available here.
PDF is available here.
Attraction and activation of dendritic cells at the site of tumor elicits potent antitumor immunity.
Abstract
We developed an in situ tumor vaccine with the ability to elicit antitumor immunity. This vaccine comprised an E1B-deleted oncolytic adenovirus expressing beta-defensin-2 (Ad-BD2-E1A) for releasing tumor antigens, recruiting and activating plasmacytoid dendritic cells (pDCs). Intratumoral injections...
|
PMID: 19532135
PDF is available here.
PDF is available here.
Abstract
Metastatic cancer remains difficult to treat effectively and treatments are in most cases not curative despite significant side effects. Novel, targeted approaches such as gene therapy hold promise for the treatment of various tumor types. Among the most promising cancer gene therapy approaches are...
|
PMID: 19785073
PDF is available here.
PDF is available here.
Cell Cycle (8)14 2009
Abstract
We determined whether hypoxic MDA-MB-231 and MCF-7 cells were more permissive to R3616, compared to normoxic cells. We observed nine-fold higher (3.5 x 10e6 pfu/4 x 10e5 pfu/ml) titers in MDA-MB-231 hypoxic cells compared to normoxic; however, hypoxic MCF-7 cells did not yield higher R3616 titers. M...
|
PMID: 19502787
PDF is available here.
PDF is available here.
Chemical Reviews (109)7 2009
Abstract
Gene Therapy (16)7 2009
Abstract
We set out to examine the oncolytic effect of HSV-1 on orthotopic rectal tumors in mice. Two vectors were compared for oncolytic activity, HSV-1(Gbeta) with wild-type replication and an attenuated HSV-1 vector (HSV-G47Delta). Intratumoral injection of HSV-1(Gbeta) and HSV-G47Delta resulted in a sign...
|
PMID: 19440231
PDF is available here.
PDF is available here.
Anticancer Research (29)6 2009
Abstract
HSV1790 + CB1954 in vitro was more effective at killing tumor cells than the virus or the prodrug alone. In vivo, the combination reduced tumor volume and increased survival compared to treatment with HSV1790 or CB1954 alone. Following systemic administration of HSV1790, viral replication was detect...
|
PMID: 19528476
PDF is available here.
PDF is available here.
Abstract
Cancer treatment with oncolytic viruses is at a crucial intersection from where two very different routes can be taken. The key role of the immune system needs to be addressed proactively to succeed. An immunocentric point of view posits that the intense immunosuppression induced by tumors can be ou...
|
PMID: 19492964
PDF is available here.
PDF is available here.
Gene Therapy (16)6 2009
Abstract
We hypothesize that a recombinant NDV expressing IL-2 would be an effective agent for therapy of malignant melanoma. We show that recombinant NDV possesses a strong cytolytic activity against multiple melanoma cell lines, and is effective in clearing established syngeneic melanoma tumors in mice. Mo...
|
PMID: 19242529
PDF is available here.
PDF is available here.
Abstract
We evaluated the capacity of EV1 for anti-neoplastic cell action in gastric peritoneal carcinomatosis. Flow cytometric analysis demonstrated that alpha(2)beta(1) was abundantly surface expressed on a panel of gastric cancer cell lines, rendering the majority of lines highly susceptible to in vitro l...
|
PMID: 19139835
PDF is available here.
PDF is available here.
Abstract
We constructed a conditionally replicative adenoviral vector (CRAd) that utilizes the survivin promoter and examined the mechanism of CRAd induced cell death in malignant glioma. Our results indicate that CRAd vectors which utilize the survivin promoter effectively replicate in glioma cells and exhi...
|
PMID: 19212678
PDF is available here.
PDF is available here.
Abstract
These results illustrate the potential of telomerase-specific oncolytic viruses for treatment of human SCCHN....
|
PMID: 19216621
PDF is available here.
PDF is available here.
Neurological Research (31)1 2009
Abstract
V4UPM, the avirulent strain of NDV, was propagate and screened for the cytolytic activity towards DBTRG.05MG and U-87MG using MTT assay. The inhibition concentration 50% (IC(50)) values by monolayer method measured at hour 72 were 23 and 9 HAU/ml, respectively. Further study was carried out to obser...
|
PMID: 18937888
PDF is available here.
PDF is available here.
Abstract
We report in this paper the intraperitoneal H101 in 9 patients with malignant ascites. The interval between the paracentesises increased from a mean of 12.4+/- 3.4 to 39.9 +/- 11.6 days (p < 0.001). The 30-day response was classified into complete response (CR) (no fluid recurrence), partial respons...
|
PMID: 19216627
PDF is available here.
PDF is available here.
Abstract
Viruses have adapted through millennia of evolution to effectively invade and lyse cells through diverse mechanisms. Strains of the attenuated measles virus Edmonston (MV-Edm) vaccine lineage can preferentially infect and destroy cancerous cells while sparing the surrounding tissues. This specificit...
|
PMID: 19169959
PDF is available here.
PDF is available here.
Journal of Immunotherapy (32)2 2009
Abstract
We describe a potent in situ vaccine targeting tumoral DCs in vivo. This vaccine comprised of an oncolytic adenovirus expressing RANTES (regulated upon activation, normally T expressed, and presumably secreted) (Ad-RANTES-E1A), enhanced tumor infiltration, and maturation of Ag-presenting cells in vi...
|
PMID: 19238013
PDF is available here.
PDF is available here.
Abstract
Measles virus offers an ideal platform from which to build a new generation of safe, effective oncolytic viruses. Occasional so-called spontaneous tumor regressions have occurred during natural measles infections, but common tumors do not express SLAM, the wild-type MV receptor, and are therefore no...
|
PMID: 19203112
PDF is available here.
PDF is available here.
Acta Virologica (53)1 2009
Abstract
Standard therapies such as surgery and chemotherapy offer only minimal improvement in pancreatic cancer. However, the viruses killing cancer cells and substances like some antibiotics and phytoalexins with anticancer potential may represent a candidate non-conventional mean of cancer treatment in th...
|
PMID: 19301953
PDF is available here.
PDF is available here.
Abstract
We discuss methods used to develop and characterize an oncolytic HSV virus that combines expression of a highly potent prodrug activating gene (yeast cytosine deaminase/uracil phosphoribosyltransferase fusion [Fcy::Fur]) and the fusogenic glycoprotein from gibbon ape leukemia virus (GALV) for enhanc...
|
PMID: 19565922
PDF is available here.
PDF is available here.
Abstract
We will therefore discuss potential viral virulence genes and metabolic targets that result in tumor-selective vaccinia strains. Because the virus has limited natural requirements for host cell proteins, and, instead, contains a large genome and multiple genes involved in virulence, a large number o...
|
PMID: 19565925
PDF is available here.
PDF is available here.
Abstract
We present the design of a phase I clinical trial combining intratumoral injections of the oncolytic adenovirus ONYX-015 with systemic chemotherapy in patients with advanced sarcomas....
|
PMID: 19565928
PDF is available here.
PDF is available here.
Oncology Reports (21)1 2009
Abstract
We have previously shown that coxsackie-adenovirus receptor (CAR) is expressed at decreased levels in several primary head and neck squamous cell carcinoma (HNSCC) cell lines established from tumor samples and that retargeting adenoviral infection to the CD46 receptor using the Ad5/35 hybrid virus r...
|
PMID: 19082458
PDF is available here.
PDF is available here.
Abstract
Viruses have been engineered for cancer therapy in a variety of ways. Approaches include non-replicating gene therapy vectors, cancer vaccines and oncolytic viruses, but the clinical efficacy of these approaches has been limited by multiple factors. However, a new therapeutic class o...
|
PMID: 19104515
PDF is available here.
PDF is available here.
Archivum Immunologiae et Therapiae Experimentalis (56 Suppl 1)s1 2008
Abstract
Based on personal acquaintances and experience dating back to the early 1950s, the senior author reviews the history of viral therapy of cancer. He points out the difficulties encountered in the treatment of human cancers, as opposed by the highly successful viral therapy of experimentally maintaine...
|
PMID: 19104757
PDF is available here.
PDF is available here.